Novartis: confirms it annual forecasts
(CercleFinance.com) - Novartis has communicated results over and above expectations this morning, and has confirmed its forecasts for the financial year as a whole.
The Swiss pharma giant has reported a turnover of 13.1 billion dollars for the 2nd quarter of its 2018 financial year, i.e. +7% in this currency and +5% at constant exchange rates. Sales of drugs Cosentyx, Entresto and oncology products have notably contributed to this increase.
Core operational results were up 7% to 3.5 billion dollars (+9% excluding currency effects), and net profits up 3% to 3 billion (+5%), or 1.29 dollars per share.
The Basel-based Group has also confirmed its forecasts for the 2018 financial year: although those for sales of Sandoz have been revised downwards, those for sales of Alcon have been revised upwards.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Swiss pharma giant has reported a turnover of 13.1 billion dollars for the 2nd quarter of its 2018 financial year, i.e. +7% in this currency and +5% at constant exchange rates. Sales of drugs Cosentyx, Entresto and oncology products have notably contributed to this increase.
Core operational results were up 7% to 3.5 billion dollars (+9% excluding currency effects), and net profits up 3% to 3 billion (+5%), or 1.29 dollars per share.
The Basel-based Group has also confirmed its forecasts for the 2018 financial year: although those for sales of Sandoz have been revised downwards, those for sales of Alcon have been revised upwards.
Copyright (c) 2018 CercleFinance.com. All rights reserved.